Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05702398 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Supplemental Vitamin A and Nicotinamide
A Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients, sponsored by Rhode Island Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05702398 is a Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 30 participants, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05702398, a Early Phase 1 study of Skin Cancer and Kidney Transplant Recipients, is actively recruiting participants, sponsored by Rhode Island Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention clinical trials.
Conditions Studied
Interventions
- DRUG Nicotinamide
- DRUG Vitamin A
- OTHER Other: Placebo
Study Locations (1)
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2028-03-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05702398
The ClinicalTrials.gov registry entry for NCT05702398 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 463-participant average among 40 other Skin Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Skin Cancer appearing as the primary indexed condition, and to 3 interventions - of which Nicotinamide is the first listed.
NCT05702398 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT05702398 about?
NCT05702398 is a clinical study titled "Pilot Trial of Supplemental Vitamin A and Nicotinamide". The goal of this clinical trial is to assess the feasibility and safety of oral nicotinamide (NAM; a derivative of vitamin B3 \[niacin\]) and vitamin A in a high-risk population of kidney transplant recipients with a history of skin cancer to generate preliminary data for future cancer prevention cl...
What is the current status of trial NCT05702398?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-04-01. Estimated completion is 2028-03-01.
What conditions does trial NCT05702398 study?
This clinical trial studies the following conditions: Skin Cancer, Kidney Transplant Recipients.
What interventions are being tested in trial NCT05702398?
The interventions under investigation include: Nicotinamide (DRUG), Vitamin A (DRUG), Other: Placebo (OTHER).
Who is sponsoring clinical trial NCT05702398?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05702398 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
RECRUITING · Early Phase 1
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.